Issue |
Vet. Res.
Volume 39, Number 6, November-December 2008
|
|
---|---|---|
Number of page(s) | 13 | |
DOI | https://doi.org/10.1051/vetres:2008037 | |
Published online | 09 September 2008 | |
How to cite this article | Vet. Res. (2008) 39:60 |
DOI: 10.1051/vetres:2008037
Construction and testing of a novel host-range defective myxoma virus vaccine with the M063 gene inactivated that is non-permissive for replication in rabbit cells
Mathew M. Adams1, 2, Barbara H. van Leeuwen1, Grant McFadden3 and Peter J. Kerr41 School of Biochemistry and Molecular Biology, College of Science, The Australian National University, Canberra, ACT 0200, Australia
2 Current address: Johnson and Johnson Research Pty Ltd, Level 4, 1 Central Avenue, Eveleigh, NSW 1430, Australia
3 Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, 1600 SW Archer Rd, Academic Research Building, PO Box 100266, Gainesville 32610, Florida, USA
4 CSIRO Entomology, GPO Box 1700, Canberra, ACT 2601, Australia
Received 23 January 2008; accepted 4 September 2008; published online 9 September 2008
Abstract - Deletion of the M063 gene from myxoma virus produces a virus that is unable to replicate in rabbit cells in vitro or in live rabbits but can be propagated in non-rabbit cell lines. A targeted M063 deletion mutant was constructed in the attenuated Uriarra strain of myxoma virus and the ability of this virus to act as a safe, non-transmissible vaccine against myxomatosis was tested in outbred laboratory rabbits. Immunization with the M063 deletion vaccine provided good short-term protection against lethal challenge with virulent myxoma virus. Long-term protection was similar to reported results with heterologous live virus, with some rabbits protected but others succumbing to challenge. Replication-deficient poxvirus vaccines, like the Modified Vaccinia Virus Ankara (MVA) in man and the myxoma virus vaccine described here in rabbits, are very attractive from a safety perspective. Seasonal boosting would be predicted to provide long-term protection. Targeted host-range gene deletions could have potential for rapid development of poxvirus vaccines in general.
Key words: myxomatosis / vaccine / host-range / poxvirus / rabbits
Corresponding author: peter.kerr@csiro.au
© INRA, EDP Sciences 2008